Clinical Trial Update: A Trial to Evaluate the Efficacy of Pioglitazone to Promote Renal Tolerance in ANCA-associated Vasculitis - RENATO Trial [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial (RENATO) evaluating pioglitazone to promote renal tolerance in ANCA-associated vasculitis is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anca-associated Vasculitis
• Crescentic Glomerulonephritis
• Rapidly Progressive Glomerulonephritis

Drugs mentioned

• PIOGLITAZONE (Pioglitazone)

Snippet

Sponsor: Assistance Publique - Hôpitaux de Paris | Conditions: ANCA Associated Vasculitis, Rapidly Progressive Glomerulonephritis | Phase 3 | Status: RECRUITING